Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume -, Issue -, Pages 115928
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.ejmech.2023.115928
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies
- (2023) Carlo Marotta et al. INORGANICA CHIMICA ACTA
- Transient pemigatinib-induced subretinal fluid accumulation and serous retinal detachment
- (2022) William R. Bloom et al. Clinical and Experimental Optometry
- An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors
- (2022) Yoshito Komatsu et al. INVESTIGATIONAL NEW DRUGS
- Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
- (2022) Lipika Goyal et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug repurposing—an emerging strategy in cancer therapeutics
- (2022) Khadija Shahab Turabi et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Liquid Biopsy: From Discovery to Clinical Application
- (2021) Catherine Alix-Panabières et al. Cancer Discovery
- Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone
- (2021) Bengt Glimelius et al. CANCER TREATMENT REVIEWS
- Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis
- (2021) Liangliang Dong et al. Clinical Breast Cancer
- FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
- (2020) Lipika Goyal et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
- (2020) Angela Lamarca et al. JOURNAL OF HEPATOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Ripretinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2020) Jean-Yves Blay et al. LANCET ONCOLOGY
- Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
- (2020) Michael C Heinrich et al. LANCET ONCOLOGY
- Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
- (2019) Bryan D. Smith et al. CANCER CELL
- Avapritinib, a selective inhibitor of KIT and PDGFRα reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines
- (2019) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- The clinical application of fruquintinib on colorectal cancer
- (2019) Zhongguang Chen et al. Expert Review of Clinical Pharmacology
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Development of encorafenib for BRAF-mutated advanced melanoma
- (2018) Peter Koelblinger et al. CURRENT OPINION IN ONCOLOGY
- Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
- (2018) Rui-Hua Xu et al. LANCET ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Encorafenib and Binimetinib: First Global Approvals
- (2018) Matt Shirley DRUGS
- Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
- (2018) Rashmi R. Shah et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
- (2016) Giandomenico Roviello et al. CANCER LETTERS
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats
- (2016) Chenrui Li et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells
- (2016) Reem T. Attia et al. PeerJ
- Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
- (2015) N. Normanno et al. ANNALS OF ONCOLOGY
- Magnetic nanoparticle-based drug delivery for cancer therapy
- (2015) Rainer Tietze et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)
- (2015) Han-Jie Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- Management of regorafenib-related toxicities: a review
- (2015) Saravanan K. Krishnamoorthy et al. Therapeutic Advances in Gastroenterology
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
- (2014) Qiaoling Sun et al. CANCER BIOLOGY & THERAPY
- Thymidine phosphorylase influences [18F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer
- (2014) Seung Jin Lee et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- What Is the Value of the Routine Use of Patient-Reported Outcome Measures Toward Improvement of Patient Outcomes, Processes of Care, and Health Service Outcomes in Cancer Care? A Systematic Review of Controlled Trials
- (2014) Grigorios Kotronoulas et al. JOURNAL OF CLINICAL ONCOLOGY
- TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90 and , Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
- (2014) S. Ohkubo et al. MOLECULAR CANCER THERAPEUTICS
- Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis
- (2013) Wei-Xiang Qi et al. Asian Pacific Journal of Cancer Prevention
- An Efficient Semi-Synthetic Method to Construct Docetaxel via Sterically Crowded Linear Side Chain Esterification
- (2013) Xin Shen et al. CHINESE JOURNAL OF CHEMISTRY
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
- (2013) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
- (2012) David J. Newman et al. JOURNAL OF NATURAL PRODUCTS
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Facile Total Synthesis for Large-Scale Production of Imatinib Base
- (2012) Amala Kompella et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity
- (2011) Paulo M. Hoff et al. Clinical Colorectal Cancer
- Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography–tandem mass spectrometry
- (2011) Ling-Zhi Wang et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
- (2011) J. M. Senra et al. MOLECULAR CANCER THERAPEUTICS
- The status of platinum anticancer drugs in the clinic and in clinical trials
- (2010) Nial J. Wheate et al. DALTON TRANSACTIONS
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- The role of chemokines in intestinal inflammation and cancer
- (2009) Dingzhi Wang et al. CURRENT OPINION IN PHARMACOLOGY
- Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s
- (2008) Henrike E. Karim-Kos et al. EUROPEAN JOURNAL OF CANCER
- Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied
- (2008) Daniela A. Brito et al. JOURNAL OF CELL BIOLOGY
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- Apoptosis-inducing effect of erlotinib is potentiated by 3,3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer
- (2008) Shadan Ali et al. MOLECULAR CANCER THERAPEUTICS
- Novel Lipophilic Platinum(II) Compounds of Salicylate Derivatives
- (2008) Wei-Ping Liu et al.
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started